- Home
- EDF vs AGEN Comparison
EDF vs AGEN Comparison
Compare EDF & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- AGEN
- Stock Information
- Founded
- EDF 2010
- AGEN 1994
- Country
- EDF United States
- AGEN United States
- Employees
- EDF N/A
- AGEN N/A
- Industry
- EDF Investment Managers
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDF Finance
- AGEN Health Care
- Exchange
- EDF Nasdaq
- AGEN Nasdaq
- Market Cap
- EDF 160.2M
- AGEN 142.8M
- IPO Year
- EDF N/A
- AGEN 2000
- Fundamental
- Price
- EDF $5.05
- AGEN $4.55
- Analyst Decision
- EDF
- AGEN Buy
- Analyst Count
- EDF 0
- AGEN 2
- Target Price
- EDF N/A
- AGEN $14.50
- AVG Volume (30 Days)
- EDF 160.6K
- AGEN 395.5K
- Earning Date
- EDF 01-01-0001
- AGEN 11-11-2025
- Dividend Yield
- EDF 13.14%
- AGEN N/A
- EPS Growth
- EDF N/A
- AGEN N/A
- EPS
- EDF N/A
- AGEN N/A
- Revenue
- EDF N/A
- AGEN $101,706,000.00
- Revenue This Year
- EDF N/A
- AGEN $60.49
- Revenue Next Year
- EDF N/A
- AGEN N/A
- P/E Ratio
- EDF N/A
- AGEN N/A
- Revenue Growth
- EDF N/A
- AGEN N/A
- 52 Week Low
- EDF $3.51
- AGEN $1.38
- 52 Week High
- EDF $5.50
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- EDF 44.55
- AGEN 48.05
- Support Level
- EDF $4.97
- AGEN $4.36
- Resistance Level
- EDF $5.09
- AGEN $5.20
- Average True Range (ATR)
- EDF 0.06
- AGEN 0.27
- MACD
- EDF -0.01
- AGEN 0.04
- Stochastic Oscillator
- EDF 34.78
- AGEN 40.91
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).